Researchers demonstrated that prostatic hyperplasia is caused by using aromatase inhibitors to decrease oestrogen, leading to hyperphosphatemia and lowering dihydroxy vitamin D levels (Cheboub et al. Here, CYP19A1 is linked to prostate disorder.